Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25601341

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Feb
First author
Ryan CJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Feb;16(2):119-21. doi: 10.1016/S1470-2045(15)70005-7.
    note
    Source null
    related pmid
    25601338
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2015 Mar;12(3):120. doi: 10.1038/nrurol.2015.14.
    note
    Source null
    related pmid
    25644162
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2015 Mar;12(3):128. doi: 10.1038/nrclinonc.2015.14.
    note
    Source null
    related pmid
    25645601
    relationship
    Comment in

Authors and identifiers

  1. name
    Ryan CJ
    type
    Author
  2. name
    Smith MR
    type
    Author
  3. name
    Fizazi K
    type
    Author
  4. name
    Saad F
    type
    Author
  5. name
    Mulders PF
    type
    Author
  6. name
    Sternberg CN
    type
    Author
  7. name
    Miller K
    type
    Author
  8. name
    Logothetis CJ
    type
    Author
  9. name
    Shore ND
    type
    Author
  10. name
    Small EJ
    type
    Author
  11. name
    Carles J
    type
    Author
  12. name
    Flaig TW
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ryan CJ
    type
    Author
  2. name
    Smith MR
    type
    Author
  3. name
    Fizazi K
    type
    Author
  4. name
    Saad F
    type
    Author
  5. name
    Mulders PF
    type
    Author
  6. name
    Sternberg CN
    type
    Author
  7. name
    Miller K
    type
    Author
  8. name
    Logothetis CJ
    type
    Author
  9. name
    Shore ND
    type
    Author
  10. name
    Small EJ
    type
    Author
  11. name
    Carles J
    type
    Author
  12. name
    Flaig TW
    type
    Author
bibliography ids
  1. nci-bib-54443a7fb2d740f2021fc4d7
book metadata
content sha256
df9fd2358ebd44f188607b00a3ac0ddcde93f6b545f3ed0eef380fa798590ab3
document type
citation
dois
  1. 10.1016/S1470-2045(14)71205-7
electronic publication date
display
2015 Jan 16
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25601341
immutable id
pubmed:25601341@df9fd2358ebd44f188607b00a3ac0ddcde93f6b545f3ed0eef380fa798590ab3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
152-60
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Feb;16(2):119-21. doi: 10.1016/S1470-2045(15)70005-7.
    note
    Source null
    related pmid
    25601338
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2015 Mar;12(3):120. doi: 10.1038/nrurol.2015.14.
    note
    Source null
    related pmid
    25644162
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2015 Mar;12(3):128. doi: 10.1038/nrclinonc.2015.14.
    note
    Source null
    related pmid
    25645601
    relationship
    Comment in
outcomes validated
false
pmid
25601341
provenance
batch id
863b068fe5a07222af6a
provider
NCBI PubMed ESummary
record sha256
c49c2a0bef466aa930d30279b8c6af171dd8a255c2236029b24405253cd95148
response sha256
80b1cc99e93fcfceb3e1b12ea433c615b032a2db13a615db7a6e9382c17c5034
retrieved at
2026-09-09T23:47:07.648963+00:00
publication date
display
2015 Feb
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25601341/
title
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Preserved source evidence · Not medical advice